Toyoaki Hida

Sapporo Medical University — Japan

Medicine · Health Sciences

75h-index28.5kcitations445works13.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(266), Lung Cancer Research Studies(133), Lung Cancer Diagnosis and Treatment(99), Colorectal Cancer Treatments and Studies(77), Cancer Immunotherapy and Biomarkers(64)

Publications441 total

Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study
Journal of Clinical Oncology·2025· 12 citedOpen Access
Cerebrospinal fluid cytology for the diagnosis of lung cancer brain metastasis: a case report
Translational Lung Cancer Research·2025Open Access
First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial
Lung Cancer·2025· 4 citedOpen Access
Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC
npj Precision Oncology·2025· 2 citedOpen Access
An Excerpt Highlighting Differences Between Japanese and Western Melanoma Clinical Guidelines
EJC Skin Cancer·2025Open Access
The current landscape and prospects of antibody-drug conjugates for lung cancer brain metastases: a narrative review
Translational Lung Cancer Research·2024· 9 citedOpen Access
Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial
JTO Clinical and Research Reports·2024· 12 citedOpen Access
A rare case report of a primary lung cancer comprising adenocarcinoma and atypical carcinoid tumor, with the carcinoid component harboring EML4-ALK rearrangement
Translational Lung Cancer Research·2024· 1 citedOpen Access
Antibody-drug conjugate development: opening windows for EGFR-mutant EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancers?
Translational Lung Cancer Research·2024· 2 citedOpen Access
Abstract 1192: Diversity of TCR repertoire on peripheral CD8+PD-1+ T-cell predicting the PFS of chemoradiotherapy followed by durvalumab maintenance in unresectable locally advanced NSCLC patients
Cancer Research·2024
PD-1-induced encephalopathy: a report of 2 cases on neurological toxicities with immune checkpoint inhibitors
Translational Cancer Research·2024· 3 citedOpen Access
Downregulation of homeobox B8 in attenuating non-small cell lung cancer cell migration and invasion though the epithelial-mesenchymal transition pathway
Translational Cancer Research·2024· 3 citedOpen Access
What is the role of consolidation immunotherapy after chemoradiotherapy in stage III EGFR-mutant non-small cell lung cancer?
AME Clinical Trials Review·2023Open Access
First‐line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non‐squamous non‐small cell lung cancer: Updated survival analysis of the <scp>ONO</scp>‐4538‐52/<scp>TASUKI</scp>‐52 randomized controlled trial
Cancer Medicine·2023· 22 citedOpen Access
Anaplastic lymphoma kinase inhibitor development: enhanced delivery to the central nervous system
Translational Lung Cancer Research·2023· 2 citedOpen Access
Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR+ non-small-cell lung cancer
Translational Lung Cancer Research·2023· 5 citedOpen Access
Supplementary Figure Legend from EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
2023Open Access
Supplementary Figure 1 from EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
2023Open Access
Supplementary Table 1 from EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
2023Open Access
Data from EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
2023Open Access
page 1 of 23Next →

Frequent Co-authors

Tetsuya Mitsudomi(16), Takashi Takahashi(13), Yasushi Yatabe(12), Makoto Nishio(11), Kazuhiko Nakagawa(11), Takashi Seto(10), Nobuyuki Yamamoto(10), Yoshitsugu Horio(8), Miyako Satouchi(8), Tomohide Tamura(7), Yoshitaka Sekido(7), Koji Takeda(6), Ji‐Youn Han(5), Fumio Imamura(5), Kōichi Goto(5), Takahiko Sugiura(5), Masahiro Fukuoka(5), Yuichiro Ohe(5), Junichi Shimizu(5), Filippo de Marinis(4)